PLA2G7 and familial isolated congenital asplenia: In conclusion, elevated Lp-PLA2 levels were associated with an increased risk of ICAS in patients with AIS, and the level of Lp-PLA2 was higher in patients who had more or severe lesions of ICAS, suggesting that Lp-PLA2 is a promising biomarker for ICAS, and may be a potential therapeutic target for ICAS.